In just a few years, CRISPR, the revolutionary gene editing technology, has become science’s “it” discipline, giving birth to a bitter patent dispute, billions in biotech investments, and an in-development primetime TV drama. But unlike the comparatively less buzzy pursuits of virology and animal husbandry, CRISPR has lacked one of academia’s unsexier badges of honor: a peer-reviewed journal to call its own.
That’s going to change come 2018 with the arrival of The CRISPR Journal, a bimonthly publication that seeks to chronicle every breakthrough, ethical debate, and legal quandary in the world of gene editing.
About the Author Reprints
